Eisai Primes Push For Biogen MS Range In India
Executive Summary
Eisai is straddling a mix of new opportunities for growth in India as it takes charge of sales of Biogen’s multiple sclerosis portfolio in the country and also eyes potential gains from its Japanese parent’s recent deal with Nichi-Iko.
You may also be interested in...
Entrepreneurship Beckons As Eisai India Chief Departs
Eisai Pharmaceuticals India's managing director has left the company and plans to start his own venture.
Interview: Eisai India Unit’s Pivotal Role As Japan Genericizes
Eisai India chief Dr. Sanjit Singh Lamba outlines the competitive edge that the Japanese group’s Indian site offers under the deal with Nichi-Iko; the site has also never “depended” on active pharmaceutical ingredients from China. In a wide-ranging interview with Scrip, Lamba also discusses recent quality compliance initiatives in India.
Deal Watch Asia Focus: Pfenex Licenses Asian Rights To Forteo Copy To NT Pharma Group
Otsuka obtains Japanese rights to two cancer gene therapy candidates from Takara. GlaxoSmithKline extends its protein degradation collaboration with Kymera.
Need a specific report? 1000+ reports available
Buy Reports